Evidence map›Paper›PMID 41983112›Full record

ArticleEuropean heart journal open2026

Evaluation after delayed and repeated intervention in the VIPVIZA-extended randomized controlled trial: beneficial results 6 years after baseline.

Margareta Norberg, Patrik Wennberg, Per Wester, Anders Själander, Per Liv

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01849575 (Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01849575 naactive not recruitingnot on this map

Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme (VIP) and Ordinary Care.

TypeinterventionalSponsorUmeå UniversityRan2013 to 2027Enrolled3,532ConditionsCardiovascular DiseasesArmsIntervention
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Margareta NorbergDepartment of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.ORCID https://orcid.org/0000-0003-2475-7131
Patrik WennbergDepartment of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.ORCID https://orcid.org/0000-0002-1617-6102
Per WesterDepartment of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.ORCID https://orcid.org/0000-0003-0394-5096
Anders SjälanderDepartment of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.ORCID https://orcid.org/0000-0001-9422-1186
Per LivDepartment of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.ORCID https://orcid.org/0000-0002-5494-8134

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The Västerbotten Intervention Programme VIsualiZation of subclinical Atherosclerosis (VIPVIZA) pragmatic randomized controlled trial (RCT) previously reported reduced cardiovascular disease (CVD) risk 3 years after colour-coded information about subclinical atherosclerosis based on carotid ultrasonography and facilitated by nurse-led motivational dialogue. This report evaluated the development of CVD risk and clinical risk factors following the 3-year follow-up, at which point the control group received their first delayed intervention and the intervention group received a repeated VIPVIZA intervention. Methods and results: Participants ( Conclusion: When the delayed VIPVIZA intervention was provided to the control group after 3 years, the beneficial effect appeared similar as previously reported for the intervention group. After 6 years, any differences between groups in CVD risk were no longer seen. Cholesterol levels were greatly reduced in both groups. Registration: The VIPVIZA trial is registered with www.clinicaltrials.gov (NCT01849575).

Indexed as

AtherosclerosisCardiovascular riskCardiovascular risk factorsPrimary preventionRandomized controlled trialUltrasound imaging

Identifiers

PMID41983112
PMCPMC13075482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.